Table. 1.

Inhibition effect of SARS-CoV-2 and survival cell ratio by concentration in comparison group

Substance Concentration
(µM)
Inhibition-normalized infection ratio Cell number to mock (%) IC50 CC50 SI
1st 2nd 1st 2nd
Chloroquine 150.00 100.19 99.06 2.00 2.34 9.38 87.04 9.28
75.00 99.75 100.19 78.24 78.12
37.50 100.16 99.87 91.32 90.90
18.75 99.84 98.05 97.63 98.61
9.38 42.77 55.77 99.33 102.68
4.69 3.45 6.65 95.49 95.49
2.34 -0.41 1.70 95.02 94.94
1.17 -0.26 -0.36 93.64 94.33
0.59 0.23 0.15 96.10 93.39
0.29 -0.31 -1.60 94.77 92.36
Remdesivir 50.00 98.08 98.04 105.93 107.88 10.96 >50 4.56
25.00 91.62 96.11 107.21 107.78
12.50 61.28 63.00 106.05 105.44
6.25 12.27 8.18 104.53 99.62
3.13 2.63 6.05 97.68 98.74
1.56 0.69 2.51 97.33 98.93
0.78 0.61 2.76 98.34 98.24
0.39 1.50 2.36 98.00 93.02
0.20 2.97 0.18 99.67 98.42
0.10 -0.83 1.26 97.83 98.59
Lopinavir 50.00 100.19 100.14 50.55 52.03 14.27 >50 3.50
25.00 100.13 100.19 86.30 82.65
12.50 4.74 12.55 89.97 88.78
6.25 -1.76 1.09 94.89 90.31
3.13 0.24 0.14 96.77 92.41
1.56 -0.40 -0.27 95.66 94.55
0.78 -0.19 0.99 93.47 97.55
0.39 -0.58 0.22 91.59 94.82
0.20 1.63 0.63 94.23 90.85
0.10 0.59 0.12 94.23 91.57

IC, inhibitory concentration; CC, cytotoxic concentration; SI, selectivity index.

Korean J Fam Pract 2021;11:312~321 https://doi.org/10.21215/kjfp.2021.11.4.312
© KJFP